Pharmacogenetics of cancer therapy: Getting personal

[11] Genetic predisposition to the metabolism of irinotecan (CPT-11) - Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) : 847 - 854

[12] Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms [J]. PHARMACOGENETICS, 1996, 6 (04): : 279 - 290

[13] A SINGLE-POINT MUTATION LEADING TO LOSS OF CATALYTIC ACTIVITY IN HUMAN THIOPURINE S-METHYLTRANSFERASE [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (04) : 949 - 953

[14] LENNARD, 1990, J CLIN ONCOL, V8, P567

[15] GENETIC-VARIATION IN RESPONSE TO 6-MERCAPTOPURINE FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA [J]. LANCET, 1990, 336 (8709) : 225 - 229

[16] VARIABLE MERCAPTOPURINE METABOLISM AND TREATMENT OUTCOME IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) : 1816 - 1823

[17] ORAL 6-MERCAPTOPURINE IN CHILDHOOD LEUKEMIA - PARENT DRUG PHARMACOKINETICS AND ACTIVE METABOLITE CONCENTRATIONS [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) : 287 - 292

[18] POLYMORPHIC THIOPURINE METHYLTRANSFERASE IN ERYTHROCYTES IS INDICATIVE OF ACTIVITY IN LEUKEMIC BLASTS FROM CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J]. BLOOD, 1995, 85 (07) : 1897 - 1902

[19] AZATHIOPRINE-INDUCED MYELOSUPPRESSION IN THIOPURINE METHYLTRANSFERASE DEFICIENT HEART-TRANSPLANT RECIPIENT [J]. LANCET, 1993, 341 (8853) : 1151 - 1151

[20] THIOPURINE METHYLTRANSFERASE ACTIVITY IN AMERICAN WHITE SUBJECTS AND BLACK SUBJECTS [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (01) : 15 - 20

[11] Genetic predisposition to the metabolism of irinotecan (CPT-11) - Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) : 847 - 854

[12] Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms [J]. PHARMACOGENETICS, 1996, 6 (04): : 279 - 290

[13] A SINGLE-POINT MUTATION LEADING TO LOSS OF CATALYTIC ACTIVITY IN HUMAN THIOPURINE S-METHYLTRANSFERASE [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (04) : 949 - 953

[14] LENNARD, 1990, J CLIN ONCOL, V8, P567

[15] GENETIC-VARIATION IN RESPONSE TO 6-MERCAPTOPURINE FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA [J]. LANCET, 1990, 336 (8709) : 225 - 229

[16] VARIABLE MERCAPTOPURINE METABOLISM AND TREATMENT OUTCOME IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) : 1816 - 1823

[17] ORAL 6-MERCAPTOPURINE IN CHILDHOOD LEUKEMIA - PARENT DRUG PHARMACOKINETICS AND ACTIVE METABOLITE CONCENTRATIONS [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) : 287 - 292

[18] POLYMORPHIC THIOPURINE METHYLTRANSFERASE IN ERYTHROCYTES IS INDICATIVE OF ACTIVITY IN LEUKEMIC BLASTS FROM CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J]. BLOOD, 1995, 85 (07) : 1897 - 1902

[19] AZATHIOPRINE-INDUCED MYELOSUPPRESSION IN THIOPURINE METHYLTRANSFERASE DEFICIENT HEART-TRANSPLANT RECIPIENT [J]. LANCET, 1993, 341 (8853) : 1151 - 1151

[20] THIOPURINE METHYLTRANSFERASE ACTIVITY IN AMERICAN WHITE SUBJECTS AND BLACK SUBJECTS [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (01) : 15 - 20